TO THE EDITOR:

The introduction of plasmapheresis with plasma exchange has increased survival in patients with thrombotic thrombocytopenic purpura (TTP) from <10% to 80%. More than 30% of patients with TTP have at least 1 relapse within 2 years. Treatment with rituximab normalizes ADAMTS13 and induces durable remissions in >90% of patients with refractory or relapsing TTP. Rituximab is increasingly used in the upfront setting with evidence of improved rates of remission and disease-free interval.4,5 

The standard dosing regimen for rituximab is 375 mg/m2 weekly for 4 weeks, which is the dose adopted from regimens developed to treat of non-Hodgkin lymphoma. In autoimmune conditions with a lower total lymphocyte mass, an efficacious dose of rituximab is likely less than what is administered for the treatment of lymphoma. Lower doses of rituximab are attractive...

REFERENCES

REFERENCES
1.
Rock
GA
,
Shumak
KH
,
Buskard
NA
, et al;
Canadian Apheresis Study Group
.
Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura
.
N Engl J Med
.
1991
;
325
(
6
):
393
-
397
.
2.
Kremer Hovinga
JA
,
Vesely
SK
,
Terrell
DR
,
Lämmle
B
,
George
JN
.
Survival and relapse in patients with thrombotic thrombocytopenic purpura
.
Blood
.
2010
;
115
(
8
):
1500
-
1511
,
quiz 1662
.
3.
Sadler
JE
.
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura
.
Blood
.
2008
;
112
(
1
):
11
-
18
.
4.
Scully
M
,
McDonald
V
,
Cavenagh
J
, et al
.
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
.
Blood
.
2011
;
118
(
7
):
1746
-
1753
.
5.
Westwood
JP
,
Webster
H
,
McGuckin
S
,
McDonald
V
,
Machin
SJ
,
Scully
M
.
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
.
J Thromb Haemost
.
2013
;
11
(
3
):
481
-
490
.
6.
Coiffier
B
,
Lepage
E
,
Briere
J
, et al
.
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
.
N Engl J Med
.
2002
;
346
(
4
):
235
-
242
.
7.
Fattizzo
B
,
Zaninoni
A
,
Pettine
L
,
Cavallaro
F
,
Di Bona
E
,
Barcellini
W
.
Low-dose rituximab in autoimmune hemolytic anemia: 10 years after
.
Blood
.
2019
;
133
(
9
):
996
-
998
.
8.
Barcellini
W
,
Zaja
F
,
Zaninoni
A
, et al
.
Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies
.
Blood
.
2012
;
119
(
16
):
3691
-
3697
.
9.
Zaja
F
,
Vianelli
N
,
Volpetti
S
, et al
.
Low-dose rituximab in adult patients with primary immune thrombocytopenia
.
Eur J Haematol
.
2010
;
85
(
4
):
329
-
334
.
10.
Westwood
JP
,
Thomas
M
,
Alwan
F
, et al
.
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
.
Blood Adv
.
2017
;
1
(
15
):
1159
-
1166
.
11.
Benhamou
Y
,
Paintaud
G
,
Azoulay
E
, et al;
French Reference Center for Thrombotic Microangiopathies
.
Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study
.
Am J Hematol
.
2016
;
91
(
12
):
1246
-
1251
.
12.
Muia
J
,
Gao
W
,
Haberichter
SL
, et al
.
An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2013
;
11
(
8
):
1511
-
1518
.
13.
Vesely
SK
,
George
JN
,
Lämmle
B
, et al
.
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients
.
Blood
.
2003
;
102
(
1
):
60
-
68
.
14.
Scully
M
,
Cataland
SR
,
Peyvandi
F
, et al;
HERCULES Investigators
.
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
.
N Engl J Med
.
2019
;
380
(
4
):
335
-
346
.
15.
Hie
M
,
Gay
J
,
Galicier
L
, et al;
French Thrombotic Microangiopathies Reference Centre
.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
.
Blood
.
2014
;
124
(
2
):
204
-
210
.
You do not currently have access to this content.